Gilead Sciences v. Cipla: HIV Integrase Inhibitor Case Consolidated in Delaware
Gilead Sciences filed a patent infringement action against Cipla Limited in Delaware’s District Court, asserting two patents covering bictegravir, a core component of HIV integrase strand transfer inhibitor therapy. Within roughly 94 days of Cipla filing its answer, the case was consolidated with a parallel Gilead action — C.A. No. 22-615 — already involving Lupin Ltd. and Laurus Labs Limited before the same judge.
Gilead’s Multi-Defendant HIV Patent Strategy Comes Into Focus
On December 29, 2023, Gilead Sciences, Inc. filed Case No. 1:23-cv-01480 against Cipla Limited in the United States District Court for the District of Delaware, before Judge Maryellen Noreika. The action alleged infringement of US10385067B2 and US9708342B2, both directed to compositions and methods related to bictegravir — the active integrase strand transfer inhibitor in Gilead’s Biktarvy HIV regimen. Cipla’s accused product is identified by its chemical name as the sodium salt of a bicyclic pyridopyrazino-oxazepine compound central to the patents.
Cipla filed its answer on February 7, 2024. By April 1, 2024, the Court approved a stipulation consolidating this action with C.A. No. 22-615 (MN) — a pre-existing Gilead suit against Lupin Ltd. and Laurus Labs Limited asserting the same or overlapping patent claims. Consolidation was agreed by all parties, including Lupin and Laurus, and Cipla was bound into the existing Stipulated Protective Order from September 2022. The originating docket (1:23-cv-01480) was formally closed; all further proceedings occur under C.A. No. 22-615.
The 647-day duration reflects the period from filing to administrative closure upon consolidation, not a merits resolution. The consolidation is consistent with Gilead’s established litigation posture of coordinating ANDA-related patent suits against multiple generic filers before a single judge. What remains unknown from this docket alone is whether Cipla’s ANDA filing timeline, claim scope disputes, or any licensing discussions influenced the pace or terms of consolidation; those details would appear on the C.A. No. 22-615 docket going forward.
Filing to Case Consolidated in 647 days
647 days from filing to consolidation close — shorter active docket than typical ANDA patent trials, which often run 1,000+ days
Case consolidated into C.A. No. 22-615: what this means for both parties
Consolidation merges dockets — no merits ruling on this case number
Under Fed. R. Civ. P. 42(a), courts may consolidate actions sharing common questions of law or fact. Here, Judge Noreika consolidated 1:23-cv-01480 into the earlier C.A. No. 22-615 because both actions involve Gilead asserting the same HIV integrase inhibitor patents against overlapping generic defendants. The originating docket is administratively closed; no claim construction, summary judgment, or trial ruling was issued under this case number.
Rule 42(a) consolidationGilead retains unified enforcement track against all three generic challengers
Consolidation benefits Gilead by aligning Cipla’s defence schedule with that of Lupin and Laurus under the already-amended Scheduling Order. Gilead avoids duplicative discovery, parallel claim construction proceedings, and the risk of inconsistent rulings. All enforcement rights against Cipla now proceed in the consolidated action, and Cipla is bound by the same Protective Order as the other defendants.
Unified enforcement retainedCipla joins a consolidated defence alongside Lupin and Laurus Labs
Cipla enters the litigation bound by a Protective Order and scheduling framework already set by the earlier action. This limits Cipla’s ability to litigate on a separate, potentially more favourable timeline. However, consolidation also means Cipla may benefit from shared discovery and coordinated invalidity arguments developed by co-defendants Lupin and Laurus Labs, which could reduce its individual litigation costs.
Joined consolidated defenceBiktarvy patent enforcement pattern signals high generic-entry barriers
Gilead’s coordinated multi-defendant litigation strategy for bictegravir patents — consolidating suits against Cipla, Lupin, and Laurus before a single judge — is consistent with aggressive Hatch-Waxman enforcement designed to maximise the 30-month stay period and delay generic market entry. For other generic manufacturers considering ANDA filings referencing Biktarvy, this consolidated proceeding raises the litigation risk profile materially.
Hatch-Waxman enforcement signalFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Gilead Sciences, Inc. | Company | Biopharmaceutical innovator — holder of US10385067B2 and US9708342B2 covering bictegravir HIV therapySearch in Eureka ↗ |
| Defendant | Cipla Limited | Individual | Cipla Limited — Indian generic pharmaceutical manufacturer and ANDA filerSearch in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Andrew O. Larsen | Attorney | Counsel for Cipla LimitedSearch in Eureka ↗ |
| Defendant counsel | Christopher J. Sorenson | Attorney | Counsel for Cipla LimitedSearch in Eureka ↗ |
| Defendant counsel | James S. Green , Jr. | Attorney | Counsel for Cipla LimitedSearch in Eureka ↗ |
| Defendant counsel | Jason M. Wiener | Attorney | Counsel for Cipla LimitedSearch in Eureka ↗ |
| Defendant counsel | W. Reid Morris | Attorney | Counsel for Cipla LimitedSearch in Eureka ↗ |
| Defendant law firm | James S Green Jr. | Law Firm | Representing Cipla LimitedSearch in Eureka ↗ |
| Presiding judge | Judge Maryellen Noreika | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order is procedural, not a merits disposition. The stipulation confirms all parties’ consent to merge C.A. No. 23-1480 into C.A. No. 22-615 for all purposes including trial, and binds Cipla to the existing Protective Order. No claim construction, infringement finding, or invalidity ruling was issued under this docket. The outcome means substantive adjudication of Gilead’s patent rights against Cipla — and Cipla’s validity challenges — will occur exclusively under the C.A. No. 22-615 docket, making that case the controlling proceeding for assessing litigation outcome.
US10385067B2 & US9708342B2 — Bictegravir HIV Integrase Inhibitor Compositions
US9708342B2 and US10385067B2 protect compositions centred on bictegravir — chemically identified as the sodium salt of a bicyclic pyridopyrazino-oxazepine — which functions as an integrase strand transfer inhibitor (INSTI) for HIV-1 treatment. The patents derive from application numbers US14/744915 and US15/624166 respectively, reflecting a filing and continuation strategy across Gilead’s bictegravir development programme. INSTIs represent the dominant mechanistic class in modern HIV combination antiretroviral therapy due to their high barrier to resistance.
Bictegravir is the backbone of Gilead’s Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), one of the highest-revenue HIV single-tablet regimens globally. These patents function as core commercial exclusivity assets, making them high-value enforcement targets. Any generic pharmaceutical company seeking to commercialise a bictegravir-containing product in the US must navigate both patents, creating a stacked exclusivity barrier that Gilead is actively defending through multi-defendant Hatch-Waxman litigation.
Should you run an FTO analysis against US10385067B2 and US9708342B2?
Any manufacturer, formulator, or ANDA applicant working on bictegravir-containing HIV antiretroviral products — whether as standalone INSTI therapies or fixed-dose combination regimens — should treat these two patents as high-priority FTO targets. Gilead has demonstrated willingness to enforce both patents simultaneously against multiple generic entrants, and the consolidated Delaware litigation confirms active, coordinated prosecution of these rights through at least 2025.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to map claim scope across both patents, identify file wrapper prosecution history, and surface related family members that may extend beyond these two application numbers. Running a full landscape analysis against Gilead’s bictegravir patent family — before any ANDA or NDA filing — is essential for accurately scoping generic entry risk and timing commercialisation strategy.
Run a freedom-to-operate analysis on US10385067B2 to assess your product’s exposure
Run FTO in Eureka →Similar HIV Antiretroviral Patent Suits in Delaware District Court
Related Hatch-Waxman infringement actions involving HIV integrase inhibitor patents litigated in the District of Delaware, including multi-defendant ANDA consolidation matters.
What this case signals for the HIV antiretroviral IP landscape
Gilead’s multi-front patent enforcement over bictegravir has direct implications for generic entry timing and ANDA litigation strategy across the HIV therapy sector.
Consolidation amplifies Gilead’s leverage in bictegravir ANDA disputes
By consolidating three generic defendants before a single judge on a unified schedule, Gilead ensures any favourable claim construction applies simultaneously against all challengers. Generic entrants facing Hatch-Waxman suits on these patents should assume coordinated litigation posture and prepare for extended pre-trial timelines under the C.A. No. 22-615 framework.
US10385067B2 and US9708342B2 form a layered exclusivity barrier for bictegravir
Two asserted patents — one covering compositions (US9708342B2) and one a later continuation or related filing (US10385067B2) — suggest Gilead has constructed a patent family designed to extend exclusivity beyond a single expiry date. Companies developing bictegravir generics should conduct independent FTO analysis across the full patent family, not just the lead compound patent.
Gilead v Cipla — key questions answered
Case No. 1:23-cv-01480 was consolidated into C.A. No. 22-615 in the District of Delaware on April 1, 2024. Gilead filed the action on December 29, 2023, asserting US10385067B2 and US9708342B2 against Cipla over bictegravir HIV integrase inhibitor compositions. No merits ruling was issued; all further proceedings occur under the consolidated docket.
Gilead asserted US10385067B2 (application no. US15/624166) and US9708342B2 (application no. US14/744915). Both patents cover bictegravir-related HIV integrase strand transfer inhibitor compositions. Bictegravir is the active INSTI component of Gilead’s Biktarvy fixed-dose combination HIV therapy.
Consolidation under Fed. R. Civ. P. 42(a) means Cipla’s case is merged with C.A. No. 22-615 for all purposes including trial. Cipla is bound by the existing Scheduling Order and Protective Order. Cipla will litigate alongside co-defendants Lupin Ltd. and Laurus Labs Limited, potentially sharing discovery and invalidity arguments, but also subject to the timeline already set in that earlier action.
The accused product is identified chemically as sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate — the sodium salt form of bictegravir. This compound is the integrase strand transfer inhibitor active ingredient in Gilead’s Biktarvy HIV treatment.
Judge Maryellen Noreika of the United States District Court for the District of Delaware presides over both the originating case 1:23-cv-01480 and the consolidated action C.A. No. 22-615. Judge Noreika is experienced in Hatch-Waxman pharmaceutical patent litigation, having managed the multi-defendant bictegravir matter since at least 2022.
PatSnap Eureka searches patents and litigation data to answer instantly.